

**IN THE CLAIMS:**

Please amend claims 22 to 47 as follows:

22. (Amended) An isolated oligonucleotide sequence comprising a response element that binds to a nuclear receptor of the Nur family of nuclear receptors, said response element comprising nucleotide sequence  $X_8 L_6 Y_8$ , wherein:

C<sub>6</sub>  
a)  $X_8$  and  $Y_8$  are two half site sequences of 8 nucleotides which are configured as an everted repeat;

b)  $L_6$  separates said half site sequences, with L being 6 nucleotides and being independently selected from A,T,C, or G;

c)  $X_8$  having nucleotide sequence  $N_6 TT$ , and  $Y_8$  having nucleotide sequence  $AAN_6$ , wherein N is selected from A,T,C, or G, such that said sequence of  $X_8$  and  $Y_8$  share homology with the NBRE sequence defined by nucleotide the hexanucleotide sequence AGGTCA (SEQ ID NO: 3), and its complement TGACCT (SEQ ID NO: 29), respectively, and wherein said response element is capable of binding to a dimer consisting of two partners which are selected from members of the Nur family of nuclear receptors.

23. (Amended) The oligonucleotide sequence of claim 22, wherein 4 out of 6 nucleotides of  $N_6$  are identical to said AGGTCA (SEQ ID NO: 3) or TGACCT (SEQ ID NO: 29) sequences.

24. (Amended) The oligonucleotide sequence of claim 23, wherein  $AAN_6$  has a sequence selected from the group consisting of AAATATCA (SEQ ID NO:7), AAATGCCA (SEQ ID NO:8), AAAGGTCA (SEQ ID NO:1), and functional derivatives thereof.

25. (Amended) The oligonucleotide sequence of claim 23, wherein  $N_6 TT$  has a sequence selected from the group consisting of TGATATTT (SEQ ID NO: 30), TGGCATTT (SEQ ID NO: 31), TGACCTTT (SEQ ID NO: 32), and functional derivatives thereof.

26. (Amended) The oligonucleotide sequence of claim 25, wherein said response element comprises a nucleotide sequence selected from the group consisting of :

GTGATATTTXXXXXXAAATGCCAG (SEQ ID NO:9),  
TGATATTTXXXXXXAAATGCCA (SEQ ID NO:10),  
GTGATATTTXXXXXXAAATATCAC (SEQ ID NO:11),  
TGATATTTXXXXXXAAATATCA (SEQ ID NO:12),  
CTGGCATTXXXXXXAAATGCCAG (SEQ ID NO:13), TGGCATTXXXXXX  
AAATGCCA (SEQ ID NO:14),  
QTGACCTTTXXXXXXAAAGGTCAQ (SEQ ID NO:15), TGACCTTTXXXXXX  
AAAGGTCA (SEQ ID NO:16),  
QTGUYATTTXXXXXXAAATUYCAQ (SEQ ID NO:17),  
TGUYATTTXXXXXXAAATUYCA (SEQ ID NO:18),  
GTGATATTTACCTCCAAATGCCAG (SEQ ID NO:19), TGATATTTACCTCCAAA  
TGCCA (SEQ ID NO:20),  
GTGATATTTACCTCCAAATATCAC (SEQ ID NO:21),  
TGATATTTACCTCCAAATATCA (SEQ ID NO:22),  
CTGGCATTACCTCCAAATGCCAG (SEQ ID NO:23), TGGCATTACCTCCAAA  
TGCCA (SEQ ID NO:24),  
QTGACCTTTACCTCCAAAGGTCAQ (SEQ ID NO:25), TGACCTTTACCTCCAAA  
GGTCA (SEQ ID NO:26),  
QTGUYATTTACCTCCAAATUYCAQ (SEQ ID NO:27),  
TGUYATTTACCTCCAAATUYCA (SEQ ID NO:28),

complements and functional derivatives thereof, wherein X is independently selected from A,T,C, or G, U is a purine, Y is a pyrimidine, and Q is C or G.

27. (Amended) The oligonucleotide sequence of claim 26, wherein said response element comprises a nucleic acid sequence selected from the group consisting of: GTGATATTTXXXXXXAAATGCCAG (SEQ ID NO:9) and TGACCTTTXXXXXX AAAGGTCA (SEQ ID NO:16).

28. (Amended) The oligonucleotide sequence of claim 27, wherein said response element comprises nucleic acid sequence TGATATTTACCTCCAAATGCCA (SEQ ID NO:20).

29. (Previously Added) The oligonucleotide sequence of claim 28, wherein said response element comprises nucleic acid sequence  
GTGATATTTACCTCCAAATGCCAG (SEQ ID NO:19).

30. (Previously Added) The oligonucleotide sequence of claim 27, wherein said response element comprises nucleic acid sequence  
TGACCTTTXXXXXXAAAGGTCA (SEQ ID NO:16).

31. (Previously Added) The oligonucleotide sequence of claim 22, wherein said member of the Nur family of nuclear receptors is selected from the group consisting of: Nur77, NGFI-B, N10, NAK1, TR3, Nurr-1, RNR-1, NOT, TINUR, NOR-1 and MINOR.

32. (Previously Added) The oligonucleotide sequence of claim 22, wherein said response element binds to a homodimer consisting of two partners of the same member of the Nur family of nuclear receptors.

33. (Previously Added) The oligonucleotide sequence of claim 22, wherein said response element binds to a heterodimer consisting of two partners of a different member of the Nur family of nuclear receptors.

34. (Previously Added) A DNA construct comprising the oligonucleotide sequence of claim 22, operably linked to a promoter, which promoter is operably linked to a heterologous gene, wherein the DNA construct is linked in such a manner that the gene is under the transcriptional control of the oligonucleotide sequence and promoter.

35. (Previously Added) The DNA construct of claim 34, wherein said oligonucleotide sequence comprises a multimer of at least one of said response element.

36. (Previously Added) The DNA construct of claim 34, wherein the heterologous gene is a reporter gene.

37. (Previously Added) A host cell transfected with the DNA construct of claim 34.

38. (Previously Added) A method for controlled expression of a heterologous gene of interest comprising culturing a host cell according to claim 37 in the presence of an appropriate regulatory protein.

39. (Previously Added) The method according to claim 38, wherein the regulatory protein comprises a member of the Nur family of nuclear receptors.

40. (Amended) A method for detecting a modulator of transcription at a Nur response element (Nur-RE), wherein said Nur-RE is an oligonucleotide sequence comprising a response element that binds to a nuclear receptor of the Nur family of nuclear receptors, said response element comprising nucleotide sequence  $X_8 L_6 Y_8$ , wherein:

a)  $X_8$  and  $Y_8$  are two half site sequences of 8 nucleotides which are configured as an everted repeat;

b)  $L_6$  separates said half site sequences, with L being 6 nucleotides and being independently selected from A,T,C,or G;

c)  $X_8$  having nucleotide sequence  $N_6 TT$ , and  $Y_8$  having nucleotide sequence  $AAN_6$ , wherein N is selected from A,T,C,or G, such that said sequence of  $X_8$  and  $Y_8$  share homology with the NBRE sequence defined by nucleotide the hexanucleotide sequence AGGTCA (SEQ ID NO: 3), and its complement TGACCT (SEQ ID NO: 29), respectively, and wherein said response element is capable of binding to a dimer consisting of two partners which are selected from members of the Nur family of nuclear receptors ,

comprising contacting a sample with said host cell according to claim 37, and comparing the level of expression of said reporter gene in the presence of the sample and in the absence thereof.

41. (Amended) A method for measuring the ability of a compound to modulate transcription at a Nur response element (Nur-RE), wherein said Nur-RE is an oligonucleotide sequence comprising a response element that binds to a nuclear receptor of the Nur family of nuclear receptors, said response element comprising nucleotide sequence  $X_8 L_6 Y_8$ , wherein:

a)  $X_8$  and  $Y_8$  are two half site sequences of 8 nucleotides which are configured as an everted repeat;

b)  $L_6$  separates said half site sequences, with L being 6 nucleotides and being independently selected from A,T,C,or G;

c)  $X_8$  having nucleotide sequence  $N_6TT$ , and  $Y_8$  having nucleotide sequence  $AAN_6$ , wherein N is selected from A,T,C,or G, such that said sequence of  $X_8$  and  $Y_8$  share homology with the NBRE sequence defined by nucleotide the hexanucleotide sequence AGGTCA (SEQ ID NO:3), and its complement TGACCT (SEQ ID NO: 29), respectively, and wherein said response element is capable of binding to a dimer consisting of two partners which are selected from members of the Nur family of nuclear receptors,

comprising:

a) contacting said compound with said host cell of claim 37, under conditions conducive to the expression of said heterologous gene in response to said compound; and

b) comparing the level of gene expression in step a) with the level of gene expression from said host cell in the absence of said compound.

42. (Previously Added) The method of claim 41 to identify a ligand selective for Nur family transcriptional complexes.

43. (Previously Added) An isolated multimeric complex comprising at least a dimer consisting of two partners which are selected from members of the Nur family of nuclear receptors.

44. (Previously Added) The multimeric complex of claim 43, wherein said dimer is a homodimer consisting of two partners of the same member of the Nur family of nuclear receptors.

45. (Previously Added) The multimeric complex of claim 43, wherein said dimer is a heterodimer consisting of two partners of a different member of the Nur family of nuclear receptors.

46. (Previously Added) An isolated multimeric complex comprising at least a dimer consisting of two partners which are selected from members of the Nur family of nuclear receptors, wherein said complex specifically interacts with the oligonucleotide sequence of claim 22, under physiologically relevant conditions.

47. (Previously Added) A method for affecting, in a cell, multimerization of a complex comprising a dimer consisting of two partners which are selected from members of the Nur family of nuclear receptors and/or affecting an interaction of a

Appln. No. 09/319,782  
Amendment Dated June 23, 2003  
Reply to Office Action of December 24, 2003

member of the Nur family of nuclear receptors with a Nur response element as defined in claim 22, comprising an incubation of said cell *in vitro* with a composition comprising an effective amount of a compound which affects said multimerization and/or said interaction of a member of a Nur family of nuclear receptors with said Nur response element.

---